United States: If living trends today continue, it is very likely that it will become the third leading cause of death over the years, based on the experts.
A scientific paper published in the journal Nature tells that kidney disease, “the sleepy epidemic” among grown-ups, takes the third globally after cardiovascular diseases and cancer.
How does kidney disease impact individuals?
Currently, nearly 850 million people worldwide are affected by some form of kidney disease, straining taxpayer-funded Medicare plans.
The study highlights Medicare as government-funded, emphasizing that taxpayers finance government operations through taxes, thus indirectly funding kidney disease care.
Despite taxpayers bearing the financial and physical burdens of this disease, public health authorities appear to neglect the issue, as Nature reported.
Kidney Disease Overlooked by Health Authorities
Furthermore, kidney disease is excluded from the World Health Organization’s (WHO) list of fatal non-communicable diseases despite available data indicating its severity.
According to reports from dailycaller.com, the International Society of Nephrology, the American Society of Nephrology, and the European Renal Association are lobbying the WHO to include kidney disease in its priority diseases list.
The study, which was funded by the organizations, noted that even though kidney disease is primarily associated with the comorbidities of the WHO priority illnesses, “tackling diabetes and heart disease alone will not target the core drivers of a large proportion of kidney diseases.”
What are the causes of Kidney disease?
The poisoning of kidneys by toxic substances like chemicals is one of the major causes of the prevalence of this disease. Experts regard that climate change is doing nothing but deteriorating the cases, leaving the number immeasurably heightened.
Other factors include the rising levels of toxins in our environment, coupled with government neglect in controlling the disease.
According to a recent article on dailycaller.com, patients with kidney diseases pay high costs because these two industries – pharmaceutical and medical – are not thinking about finding cost-effective solutions.
The case may be, for it is mostly kidney diseases that are chronic, patients are in dire need of medication for the remainder of their lives.